<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The association between <z:e sem="disease" ids="C0013080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Down syndrome</z:e> and <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) has been well documented </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in <z:e sem="disease" ids="C0013080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Down syndrome</z:e> is usually a specific type of megakaryoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (M7, AMKL) </plain></SENT>
<SENT sid="2" pm="."><plain>A <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> generally precedes this <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain><z:e sem="disease" ids="C0013080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Down syndrome</z:e> patients with AMKL have a much better prognosis than other children with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>A case study of a 22-month-old female with <z:e sem="disease" ids="C0013080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Down syndrome</z:e> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> of a megakaryoblastic lineage is presented here </plain></SENT>
<SENT sid="5" pm="."><plain>Upon admission to a pediatric hematology/<z:hpo ids='HP_0002664'>oncology</z:hpo> clinic, flow cytometry results reported a distinct population of phenotypically abnormal myeloblasts expressing myeloid antigens and the immature cell markers </plain></SENT>
<SENT sid="6" pm="."><plain>The patient was placed on a national research group study and began chemotherapy treatment </plain></SENT>
<SENT sid="7" pm="."><plain>To date she has received two courses of <z:chebi fb="0" ids="28680">cytarabine</z:chebi> (ara-c) and <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> therapy, which were tolerated well, and is awaiting her third course </plain></SENT>
<SENT sid="8" pm="."><plain>Her blood counts stabilize for a while after treatments and her prognosis is good </plain></SENT>
</text></document>